Decoy Therapeutics Inc. (DCOY): who owns it and who trades it
As of Nov 16, 2026, DCOY insiders reported 2 open-market sales worth $17 and 2 purchases worth $19.8K in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Arnold C Hanish (Director), with $17.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Insider trades
In the last 12 months, DCOY insiders reported $19.8K of open-market purchases and $17 of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Dec 30, 2025 | Arnold C Hanish | Director | Sale | 15 | $0.64 | $10 | Form 4 |
| Dec 30, 2025 | Arnold C Hanish | Director | Sale | 12 | $0.64 | $8 | Form 4 |
| Nov 20, 2025 | Arnold C Hanish | Director | Purchase | 5,000 | $0.75 | $3.8K | Form 4 |
| Nov 20, 2025 | Mark J Rosenblum | CFO | Purchase | 20,000 | $0.80 | $16K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Mark J Rosenblum | Exec VP Finance, CFO | $16K | – | Nov 20, 2025 |
| Arnold C Hanish | Director | $3.8K | $17 | Dec 30, 2025 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DCOY short interest
High short interest. 15.2% of DCOY shares are sold short: about 1 share in 7. Over the last 12 reports the number of shares short went up 1071%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 99,728 DCOY shares were sold short, 15.2% of the shares outstanding, up 2.2% from the report before. At the average daily volume of 54,726 shares, buying them all back would take about 1.8 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 99,728 | 15.22% | +2% | 54,726 | 1.8 |
| Oct 15, 2026 | 97,605 | 14.90% | -35% | 119,437 | 1.0 |
| Sep 30, 2026 | 150,336 | 22.95% | +1321% | 11.99M | 1.0 |
| Sep 15, 2026 | 10,578 | 1.61% | -20% | 36,775 | 1.0 |
| Aug 31, 2026 | 13,152 | 2.01% | +23% | 20,481 | 1.0 |
| Aug 14, 2026 | 10,675 | 1.63% | -58% | 34,121 | 1.0 |
| Jul 31, 2026 | 25,246 | 4.75% | +5% | 107,883 | 1.0 |
| Jul 15, 2026 | 23,986 | 4.51% | -85% | 44,863 | 1.0 |
| Jun 30, 2026 | 156,313 | 29.38% | +7851% | 1.22M | 1.0 |
| Jun 15, 2026 | 1,966 | 0.37% | -79% | 18,536 | 1.0 |
| May 29, 2026 | 9,158 | 1.72% | +8% | 14,898 | 1.0 |
| May 15, 2026 | 8,514 | 1.60% | -25% | 8,258 | 1.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Decoy Therapeutics company events
Decoy Therapeutics filed 14 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership, listing). The latest was on Sep 23, 2026.
- Sep 23, 2026AgreementDecoy Therapeutics Inc. entered into a warrant inducement letter agreement with a holder of the Company’s outstanding Series A, Series B and Series C milestone-based common warrants issued on June 29, 2026, pursuant to which the Holder agreed to exercise for cash, in full, the Series B Milestone… Filing
- Sep 15, 2026VoteReported shareholder vote results. Filing
- Jul 15, 2026VoteReported shareholder vote results. Filing
- Jun 29, 2026AgreementDecoy Therapeutics Inc., a Delaware corporation, entered into a Securities Purchase Agreement with an institutional and accredited investor for a private placement of the Company’s securities. Filing
- May 19, 2026AnnouncementOf this Current Report on Form 8-K is incorporated by reference into this Item 5.08. Filing
- Apr 2, 2026AnnouncementAs previously reported, on December 31, 2025, Decoy Therapeutics Inc. received written notice from The Nasdaq Stock Market LLC notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of the Company’s common stock for the last 30… Filing
- Mar 5, 2026AnnouncementThe Company issued a press release announcing the reverse split. Filing
- Feb 25, 2026VoteReported shareholder vote results. Filing
- Jan 8, 2026AnnouncementThe Company announced that it intends for its common stock to cease trading under the ticker symbol “SLRX” and begin trading under its new ticker symbol, “DCOY”, on the Nasdaq Capital Market, which the Company expects to be effective on January 8, 2026 . In connection with the Name Change, the… Filing
- Jan 2, 2026ListingSalarius Pharmaceuticals, Inc. received written notice from The Nasdaq Stock Market LLC notifying the Company that it is not in compliance with Nasdaq listing rule 5550(a)(2) because the closing bid price of the Company’s common stock for the last 30 consecutive business days was lower than the… Filing
- Jan 2, 2026VoteReported shareholder vote results. Filing
- Dec 19, 2025VoteReported shareholder vote results. Filing
- Nov 19, 2025LeadershipThe Company and each of Mr. Frederick E. Pierce, Dr. Barbara Hibner and Mr. Peter Marschel entered into employment agreements to serve as Chief Executive Officer, Chief Scientific Officer, and Chief Business Officer, respectively. Filing
- Nov 17, 2025AnnouncementShared information with investors. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Decoy Therapeutics financials
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named DCOY in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | CVI Investments, Inc. | 13G/A | 9.9% |
| Nov 16, 2026 | CVI Investments, Inc. | 13G/A | 9.9% |
Questions about Decoy Therapeutics Inc. (DCOY) stock
Are DCOY insiders buying or selling?
In the last 12 months, DCOY insiders reported 2 open-market purchases worth $19.8K and 2 sales worth $17. The latest trade was on Dec 30, 2025. See every trade.
What is the short interest in DCOY?
As of Oct 30, 2026, 99,728 DCOY shares were sold short, 15.2% of the shares outstanding, up 2.2% from the report before. At the average daily volume of 54,726 shares, buying them all back would take about 1.8 trading days (days to cover). See the history.
Executive pay
Decoy Therapeutics's chief executive was paid a total of $900K for the year ended Dec 31, 2025, up 23% from $734K the year before. In the last 12 months, Decoy Therapeutics's executives and directors bought $19.8K of stock on the open market and sold $17.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.